Psychotic exacerbation and emotional dampening in the daily life of patients with schizophrenia switched to aripiprazole therapy: A collection of standardized case reports

Therapeutic Advances in Psychopharmacology

Volumn 1, Issue 5, 2011, Pages 145-151

  Lataster, Johan ^a   Myin Germeys, Inez ^a   Wichers, Marieke ^b   Delespaul, Philippe A E G ^b   Van os, J ^b   Bak, Maarten ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

affect; antipsychotic; aripiprazole; daily life; dopamine; emotions; psychosis; schizophrenia

Indexed keywords

ARIPIPRAZOLE; DOPAMINE RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMOTION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PSYCHOLOGICAL WELL BEING; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; TREATMENT RESPONSE;

EID: 84998146016     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125311419552     Document Type: Article

References (30)

1. Adan-Manes J. Garcia-Parajua P. (2009) Aripiprazole in combination with other antipsychotic drugs may worsen psychosis. J Clin Pharm Ther 34: 245–246.
2. Artaloytia J.F. Arango C. Lahti A. Sanz J. Pascual A. Cubero P. et al. (2006) Negative signs and symptoms secondary to antipsychotics: A double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. Am J Psychiatry 163: 488–493.
3. Berridge K.C. Robinson T.E. (1998) What is the role of dopamine in reward: Hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 28: 309–369.
4. Carlsson A. (1988) The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1: 179–186.
5. Delespaul P.A.E.G. (1995) Assessing schizophrenia in daily life, University Press: Maastricht.
6. Hedlund P.B. Sutcliffe J.G. (2004) Functional, molecular and pharmacological advances in 5-Ht7 receptor research. Trends Pharmacol Sci 25: 481–486.
7. Kapur S. (2004) How antipsychotics become anti-‘psychotic’ – from dopamine to salience to psychosis. Trends Pharmacol Sci 25: 402–406.
8. Kapur S. Seeman P. (2001) Does fast dissociation from the dopamine D(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 158: 360–369.
9. Kim S.W. Shin I.S. Kim J.M. Lee J.H. Lee Y.H. Yang S.J. et al. (2009) Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia. Clin Neuropharmacol 32: 243–249.
10. Kranz G.S. Kasper S. Lanzenberger R. (2010) Reward and the serotonergic system. Neuroscience 166: 1023–1035.
11. Lataster J. Van Os J. De Haan L. Thewissen V. Bak M. Lataster T. et al. (2010) Emotional experience and estimates of D(2) receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: An experience sampling study. J Clin Psychiatry 14 December [epub ahead of print].
12. Liemburg E. Aleman A. Bous J. Hollander K. Knegtering H. (2011) An open randomized pilot trial on the differential effects of aripiprazole versus risperidone on anhedonia and subjective well-being. Pharmacopsychiatry 44: 109–113.
13. Mace S. Taylor D. (2009) Aripiprazole: Dose–response relationship in schizophrenia and schizoaffective disorder. CNS Drugs 23: 773–780.
14. McGuffin P. Farmer A. Harvey I. (1991) A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch Gen Psychiatry 48: 764–770.
15. Meltzer H.Y. (1995) The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics. J Clin Psychopharmacol 15: 2 S–3 S.
16. Mizrahi R. Mamo D. Rusjan P. Graff A. Houle S. Kapur S. (2009) The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics. Int J Neuropsychopharmacol 12: 715–721.
17. Myin-Germeys I. Nicolson N.A. Delespaul P.A. (2001) The context of delusional experiences in the daily life of patients with schizophrenia. Psychol Med 31: 489–498.
18. Myin-Germeys I. Oorschot M. Collip D. Lataster J. Delespaul P. Van Os J. (2009) Experience sampling research in psychopathology: Opening the black box of daily life. Psychol Med 39: 1533–1547.
19. Naber D. (1995) A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 10: 133–138.
20. Ohlsen R.I. Pilowsky L.S. (2005) The place of partial agonism in psychiatry: Recent developments. J Psychopharmacol 19: 408–413.
21. Pae C.U. Serretti A. Chiesa A. Mandelli L. Lee C. Lee C. (2009) Immediate versus gradual suspension of previous treatments during switch to aripiprazole: Results of a randomized, open label study. Eur Neuropsychopharmacol 19: 562–570.
22. Ramaswamy S. Vijay D. William M. Sattar S.P. Praveen F. Petty F. (2004) Aripiprazole possibly worsens psychosis. Int Clin Psychopharmacol 19: 45–48.
23. Sparshatt A. Taylor D. Patel M.X. Kapur S. (2010) A systematic review of aripiprazole – dose, plasma concentration, receptor occupancy, and response: Implications for therapeutic drug monitoring. J Clin Psychiatry 71: 1447–1456.
24. Stahl S.M. (2001a) Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, ‘Goldilocks’ actions at dopamine receptors. J Clin Psychiatry 62: 841–842.
25. Stahl S.M. (2001b) Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: Illustrating their mechanism of action. J Clin Psychiatry 62: 923–924.
26. The American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, 4th edition. text revision©. Washington DC.
27. Van Putten T. May P.R. Marder S.R. Wittmann L.A. (1981) Subjective response to antipsychotic drugs. Arch Gen Psychiatry 38: 187–190.
28. Ventura J. Green M.F. Shaner A. Liberman R.P. (1993) Training and quality assurance in the use of the expanded brief psychiatric rating scale: The ‘Drift Busters’. Int J Methods Psychiatry Res 3: 221–244.
29. Wolters H.A. Knegtering R. Wiersma D. van den Bosch R.J. (2006) Evaluation of the subjects’ response to antipsychotics questionnaire. Int Clin Psychopharmacol 21: 63–69.
30. Woods S.W. (2003) Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64: 663–667.